Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Fanying Meng(Shanghai University), Charles P. Hart(University of Auckland), Adam V. Patterson(University of Auckland), James Evans(Temple College), Christopher P. Guise(University of Auckland), Peter M. Glazer(Yale University), Alexandra M. Mowday(University of Auckland), Deepthi Bhupathi(University of Auckland), Monica Banica(University of Auckland), Robert F. Anderson(University of Auckland), Andrej Maroz(University of Auckland), Lingyun Lan(University of Auckland), Mark D. Matteucci(University of Auckland), Xiaohong Cai(Wenzhou Medical University), Gustavo Lorente(University of Auckland), Gregory C. Stachelek(Yale University)
Cited by 206
Related Papers
In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery
|Nature Communications|2016|183
Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity <i>in Vivo</i>
|Biochemistry|1996|75
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
|Clinical Cancer Research|2019|53